Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 80.4%

Neg 0% Neu 0% Pos 80.4%

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $245 to $260.